IGFBP1 and peripheral arterial disease: Given the higher risk of adverse events in female PAD patients and the limited exploration of sex-specific biomarkers in this population, this finding underscores the potential of IGFBP-1 as a particularly valuable prognostic marker in high-risk female patients [33].